Table 1 Baseline patient characteristics at time of CML-MBP treatment initiation
From: Impact of frontline treatment approach on outcomes of myeloid blast phase CML
| Characteristic | N (%); median [range] | |||
|---|---|---|---|---|
|
IC + TKI (N = 20) | HMA + TKI (N = 20) |
TKI (N = 56) |
IC (N = 8) | |
| Age, years | 47 [29–83] | 56 [37–89] | 57 [21–79] | 56 [27–74] |
| Race/ethnicity | ||||
| White, non-Hispanic | 10 (50%) | 14 (70%) | 37 (66%) | 5 (62.5%) |
| White, Hispanic | 4 (20%) | 1 (5%) | 2 (3.6%) | 0 |
| Black | 4 (20%) | 4 (20%) | 14 (25%) | 3 (37.5%) |
| Other | 0 | 0 | 1 (1.8%) | 0 |
| Not stated | 2 (10%) | 1 (5%) | 2 (3.6%) | 0 |
| Initial CML presentation as de novo MBP | 5 (25%) | 5 (25%) | 3 (5.3%) | 0 |
| Year of treatment initiation for MBP |
2013 [2007–2018] |
2013 [2003–2019] |
2004 [2000–2012] |
2003 [2000–2003] |
| Prior regimens for CML* | 1 [0–3] | 1 [0–4] | 1.5 [0–5] | 3 [0–4] |
| Prior TKI exposure | 14 (70%) | 14 (70%) | 32 (60%) | 7 (87.5%) |
| Changed TKI for MBP | 10/14 | 7/14 | 30/32 | N/A |
| BM blasts (%) | 39 [21–87] | 52 [24–91] | 47 [20–87] | 30 (20–60) |
| EM disease at diagnosis^ | 3/20 (15%) | 0/20 (0%) | 4/56 (7.1%) | 2/8 (25%) |
| Additional clonal cytogenetic abnormalities | 12 (60%) | 15 (75%) | 42 (75%) | 6 (75%) |
| T315I mutation | 3/20 (15%) | 0/14 (0%) | 1/23 (4.3%) | N/A |
| WBC (× 109/L) | 21.9 [3.1–259.3] | 37.7 [1.0–156.6] | 23.8 [0.7–363.7] | 32.4 [2.4–319] |
| Platelet (× 109/L) | 127 [7–607] | 75 [12–431] | 82 [7–1128] | 52 [21–2750] |
| Initial TKI for MBP | ||||
| Imatinib | 0 | 7 (35%) | 26 (48%) | N/A |
| Dasatinib | 10 (50%) | 11 (55%) | 12 (21%) | N/A |
| Nilotinib | 2 (10%) | 1 (5%) | 12 (21%) | N/A |
| Bosutinib | 1 (5%) | 0 (0%) | 3 (5%) | N/A |
| Ponatinib | 7 (35%) | 1 (5%) | 3 (5%) | N/A |